A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas)

Clinical Trial Grant

Duke Scholars

Principal Investigator Katherine Barnett Peters Neurosurgery, Neuro-Oncology

Awarded By

Servier Pharmaceuticals

Start Date

January 12, 2023

End Date

January 31, 2029

Awarded By

Servier Pharmaceuticals

Start Date

January 12, 2023

End Date

January 31, 2029